Skip to content

A Trial of Cooled Radiofrequency Ablation of Medial Branch Nerves for theTreatment of Lumbar Facet Syndrome

A Prospective Trial of Cooled Radiofrequency Ablation of Medial Branch Nerves for the Treatment of Lumbar Facet Syndrome

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02478437
Acronym
STU00097239
Enrollment
48
Registered
2015-06-23
Start date
2015-06-30
Completion date
2018-08-31
Last updated
2018-09-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Low Back Pain

Keywords

Lumbar Facet Syndrome

Brief summary

This study is being done to determine whether cooled radiofrequency ablation (CRFA) on the medial branch nerves of the lumbar facet joint is effective for the treatment of low back pain. CRFA blocks the nerves that carry pain signals from joints in the lower back such that the brain does not receive the message that the low back is in pain. This technique is commonly performed by burning these nerves rather freezing them, but it is suspected that freezing them results in better pain relief. The CRFA blocks has been shown to effectively treat sacroiliac joint pain (a joint in the pelvis), which is another reason that it is suspected that CRFA will be effective when treating pain related to facet joints in the low back. We are performing this study in order to determine if that is the case.

Detailed description

The CRFA blocks has been shown to effectively treat sacroiliac joint pain (a joint in the pelvis), which is another reason that it is suspected that CRFA will be effective when treating pain related to facet joints in the low back. We are performing this study in order to determine if that is the case.

Interventions

PROCEDUREConventional radiofrequency ablation (RFA)

A conventional RFA electrode with a 10mm active tip will be used. RFA lesions will be performed for 90 seconds with the maximum electrode temperature raised to 80°C.

PROCEDURECooled Radiofrequency Ablation (CRFA)

Following 18G C-RFA electrode positioning, 1cc of 2% lidocaine will be injected through the introducer needle for anesthesia during the ablation. The maximum electrode temperature is 60°C.

Sponsors

American Pain Society
CollaboratorOTHER
Northwestern University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 79 Years
Healthy volunteers
No

Inclusion criteria

* Patients with lumbar facet syndrome pain who would undergo treatment by lumbar medial branch radiofrequency ablation. * Low back pain for at least 6 months. * Pain resistant to conventional therapy including NSAIDs, opioids, muscle relaxants, oral steroids, physical therapy or chiropractic care. * Pain diagram suggesting possibility of facet-mediated pain. * Referred pain when present not beyond the knee. * Positive response to at least 1 set of diagnostic intra-articular facet injections or medial branch blocks, defined as \> 75% reduction in pain following diagnostic blocks with local anesthetic (0.5mL of 0.5% bupivacaine OR 0.5 mL of 2% lidocaine).

Exclusion criteria

* Focal neurologic signs or symptoms. * Radiologic evidence of a symptomatic herniated disc or nerve root impingement related to spinal stenosis. * Previous radiofrequency ablation treatment for similar symptoms. * Patient refusal. * Lack of consent. * Active systemic or local infections at the site of proposed needle and electrode placement. * Coagulopathy or other bleeding disorder, current use of anticoagulants or anti-platelet medications. * Allergy to medications being used for injection procedures (contrast dye, local anesthetic, IV sedative). * Inability to read English, communicate with staff, or participate in follow up. * Pregnancy. * Cognitive deficit. * Negative response to diagnostic intra-articular facet injections or medial branch blocks, defined as \< 75% reduction in pain following diagnostic blocks with local anesthetic (0.5mL of 0.5% bupivacaine OR 0.5 mL of 2% lidocaine). * Daily opiate analgesic use more exceeding 3 months prior to study inclusion. * Unstable medical or psychiatric illness.

Design outcomes

Primary

MeasureTime frameDescription
Pain improvement6 months post-procedurePercent of participants who reported 50% or greater improvement in pain

Secondary

MeasureTime frameDescription
Global pain score1 month, 3 months, 6 months and 12 months post procedureGlobal Numeric Rating Scale (NRS, 0 is no pain and 10 is worst pain imaginable)
McGill Pain Questionnaire (MPQ)1 month, 3 months, 6 months and 12 months post procedureScores are tabulated by summing values associated with each word; scores range from 0 (no pain) to 78 (severe pain).
Pain Anxiety Symptom Scale short form (PASS-20)1 month, 3 months, 6 months and 12 months post procedureThe PASS-20 assesses 4 factorially distinct components of pain-related anxiety. Each question is in a form of a 6-point Likert Scale anchored from 0 (never) to 5 (always).
Center for Epidemiologic Studies Depression short form index (CESD-10)1 month, 3 months, 6 months and 12 months post procedureThe possible range of the 10-item scale is 0 to 30, and a cut off score of ten or higher indicates the presence of significant depressive symptoms. Subjects responded to each item of the scale by rating the frequency of each mood or symptom ''during the past week'' on a four-point scale.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 22, 2026